英文药名：Kenicef intravenous(Cefodizime Sodium)
Kenicef intravenous 1g
Kenycef for intravenous injection 1g(Cefodizime Sodium)
Name of drug classification
Cephem antibiotic preparation
Kenycef for intravenous injection 1g
3-[(5-carboxylatomethyl-4-methylthiazol-2-yl) -2,3-dihydroxybenzaldehyde was used instead of Disodium (6R, 7R)-7-[ Sulfanylmethyl] -8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylate
About 217 ° C (decomposition)
0.001 or less (pH 7, octanol/aqueous solvent)
It is a white to pale yellow white crystalline powder. It is very soluble in water and hardly soluble in acetonitrile or ethanol (99.5).
Component · Content
Cefodizime sodium 1.0 g (potency) in one bottle
Patients with a history of shock due to ingredients of this drug
Indication or effect
Adaptive fungal species
Cefodizime is susceptible to Streptococcus sp., Streptococcus pneumoniae, Neisseria gonorrhoeae, Moraxella (Branhamellara), Catharillis, Escherichia coli, Citrobacter, Klebsiella, Enterobacter, Serratia, Proteus, Morganella · Morganii, Providencia, Haemophilus influenzae Streptococcus, Bacteroides, Prevotella (except Prevotella vivia)
Secondary infection with septicemia, pharyngo/laryngitis, tonsillitis (including amygdala, amygdal abscess), acute bronchitis, pneumonia, lung abscess, secondary infection of chronic respiratory lesions, cystitis, pyelonephritis, urethritis, peritonitis, Intraabdominal abscess, cholecystitis, cholangitis, hepatic abscess, Bartholinitis, intrauterine infection, uterine adnexitis, uterine fibrosis, suppurative meningitis, otitis media, sinusitis
Usually, for adults, cefodizime sodium is administered intravenously or intravenously by intravenous injection or intravenous drip by dividing 1 to 2g (potency) per day into two doses.
Usually, children are given intravenous injection or intravenous infusion intravenously 60 to 80 mg (potency)/kg a day divided into 3 to 4 times.
Incidentally, depending on age and symptoms, it will be increased or decreased accordingly. However, for refractory or severe infections, increase by 4g/day (titer) in adults to 120 mg (potency)/kg/day in children, dividedly administered.
For intravenous injection, dissolve in water for injection, physiological saline or glucose injection and inject slowly. Also, at the time of intravenous infusion, dissolve in the replacement fluid and inject it.
When using this drug, in order to prevent the development of resistant bacteria, as a rule to confirm susceptibility, only for the minimum period necessary for treatment of the disease.
Patients with a history of hypersensitivity to penicillin antibiotics
A patient having a constitution that is likely to cause an allergic symptom such as bronchial asthma, rash, urticaria or the like by himself, parents or brothers
Patient with advanced renal impairment [As the blood concentration is sustained, dosing should be administered at dosage intervals or at dosing intervals. ]
Patients with hepatic impairment [Incidence of side effects of the liver increases]
Patients with poor oral intake or patients with parenteral nutrition, patients with poor general condition [Vitamin K deficiency symptoms may occur, so observe thoroughly]
Elderly (see "Administration to the elderly" section)
Serious side effects
Expression frequency is described in [(). Unspecified frequency unknown]
As it may cause shock, observe thoroughly, if symptoms appear, discontinue administration and take appropriate measures.
Since anaphylactoid symptoms (redness, dyspnea, edema, convulsions, etc.) (less than 0.1%) may occur, observe thoroughly, if symptoms appear, discontinue administration and take appropriate measures .
Acute renal failure
Acute renal failure (less than 0.1%) may occur, so conduct observation thoroughly by periodically conducting an examination and if appropriate, take appropriate measures such as discontinue administration.
Serious colitis accompanied by bloody stools such as pseudomembranous colitis (less than 0.1%) may occur. If abdominal pain, frequent diarrhea appears, take appropriate measures such as immediately discontinue administration.
Since agranulocytosis and thrombocytopenia (less than 0.1%) may occur, observe thoroughly by conducting an examination regularly and if abnormality is found, take appropriate measures such as discontinue administration about.
Toxic epidermal necrosis (Lyell syndrome), skin mucosa ocular syndrome (Stevens-Johnson syndrome)
Toxic epidermal necrolysis, skin mucosal ocular syndrome may appear, so when such symptoms appear, administration should be stopped and appropriate measures should be taken.
In vitro antibacterial activity
It shows a broad antimicrobial spectrum for gram positive and negative aerobic bacteria and anaerobic bacteria. In particular, it has strong antibacterial activity against Gram-positive bacteria such as Streptococcus, Streptococcus pneumoniae and Gram-negative bacteria such as Neisseria gonorrhoeae, Escherichia coli, Klebsiella, Proteus, Providencia, Haemophilus influenzae. In addition, antibacterial activity has also been recognized for gram negative bacteria such as Moraxella (Branhamella) · catarrhalis, Morganella · Morganii and the like, and anaerobic bacteria of Peptostreptococcus, Bacteroides, Prevotera (except Prevotelera vivia) .
In vivo antibacterial activity
Excellent therapeutic effects are obtained in experimental infectious disease models in normal and infectious defense-reducing mice than expected from the minimum growth inhibitory concentration.
Cooperation with infection protective factors Bactericidal action
Bacteria treated with this drug are normally phagocytized and sterilized by phagocytes such as polymorphonuclear leukocytes and macrophages of mice which are normal in normal condition and reduced in infection protective ability, and cooperative bactericidal action with complement has been recognized. Furthermore, it has been confirmed that bacterial growth is suppressed in mouse intraperitoneal inoculation.
Mechanism of action
It exhibits antibacterial action by bacterial cell wall synthesis inhibition, has high affinity for penicillin-binding proteins (PBPs), and acts bactericidally. It is also stable against β-lactamase.